BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06842186 (WVE-007 in Obesity and Overweight): BVCT ex-ante prediction vs. reported outcome

On 14 May 2025, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 26 Mar 2026 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient (weight loss).

Clinical Trial

NCTID
NCT06842186
Acronym
INLIGHT
Drug Name
WVE-007
Drug MoA
antisense anti-INHBE mRNA
Drug Modality
oligonucleotide
Drug Class
First-In-Class
Therapeutic Area
Nutritional and Metabolic Diseases
Indication
Obesity and Overweight
Human Patients
296
Sponsor
Wave Life Sciences
Phase
Phase 1 Phase 2

Prediction of , index 2022

Prospective Prediction
Prediction Index
2022
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in weight reduction/total lean body mass preservation/total fat body mass reduction strongly inferior to apitegromab/retatrutide/VK2735)
Technical Prediction
FAILURE (statistically insignificant clinical benefit in weight reduction/total lean body mass preservation/total fat body mass reduction compared with placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
316 days in advance
Readout Data Interpretation
WVE-007 failed to achieve statistically significant placebo-adjusted improvement in weight reduction total fat mass reduction total lean mass preservation; generally safe and well tolerated
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient (weight loss)
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1/2a, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity
Phase
Phase 1, Phase 2
Status
Recruiting
Enrollment
296
Lead sponsor
Wave Life Sciences USA, Inc.
Conditions
Overweight and Obesity
Interventions
DRUG: WVE-007
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2025-01-31
Primary completion
2027-12
Completion
2027-12
Primary outcomes
  • The proportion of participants with adverse events (Day 1 through end of study)

NCT06842186 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials